Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for subcutaneous use. It is employed in the management of rheumatoid arthritis, psoriasis, psoriatic arthritis, acute lymphoblastic leukemia and other malignancies in patients as prescribed. GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts as a disease‑modifying agent across several inflammatory and oncologic pathways. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and decreases scaling. - Psoriatic arthritis: alleviates joint pain while treating skin symptoms. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Other malignancies: incorporated into chemotherapy regimens to inhibit tumor growth.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness affecting daily activities. - Oral mucositis: soreness or ulceration of the mouth lining. - Mild elevation of liver enzymes: transient hepatic enzyme rise.

Serious or Rare Side Effects: - Severe liver toxicity: potential hepatic failure requiring monitoring. - Pulmonary fibrosis: interstitial lung disease with breathlessness. - Bone marrow suppression: profound anemia, leukopenia or thrombocytopenia. - Renal failure: impaired kidney function leading to drug accumulation.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy contraindication: teratogenic; avoid use in pregnant or planning patients. - Renal function monitoring: adjust dose if creatinine clearance declines. - Liver function monitoring: regular tests to detect hepatotoxicity. - Hematologic monitoring: frequent blood counts to identify marrow suppression. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Penicillins (e.g., ampicillin): may reduce renal clearance of methotrexate. - Sulfonamide antibiotics: additive bone‑marrow suppression. - Live vaccines: heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: enhanced myelosuppression. - Cyclosporine: may increase methotrexate levels. - Folic acid supplements: can reduce toxicity but may lessen efficacy; adjust under medical guidance.